Best Macular Dystrophy: A Case Report
Published: 2023-05-15
Page: 49-53
Issue: 2023 - Volume 6 [Issue 1]
Sarra Lakrimi *
Department of Ophthalmology, Faculty of Medicine and Pharmacy, University Hospital Center Mohammed VIth Oujda, University Mohammed Premier Oujda, Oujda-60000, Morocco.
Malik Alkteish
Department of Ophthalmology, Faculty of Medicine and Pharmacy, University Hospital Center Mohammed VIth Oujda, University Mohammed Premier Oujda, Oujda-60000, Morocco.
Manal Chafik
Department of Ophthalmology, Faculty of Medicine and Pharmacy, University Hospital Center Mohammed VIth Oujda, University Mohammed Premier Oujda, Oujda-60000, Morocco.
Fatima Zahra Mabrouki
Department of Ophthalmology, Faculty of Medicine and Pharmacy, University Hospital Center Mohammed VIth Oujda, University Mohammed Premier Oujda, Oujda-60000, Morocco.
Siham Chariba
Department of Ophthalmology, Faculty of Medicine and Pharmacy, University Hospital Center Mohammed VIth Oujda, University Mohammed Premier Oujda, Oujda-60000, Morocco.
Asmae Maadane
Department of Ophthalmology, Faculty of Medicine and Pharmacy, University Hospital Center Mohammed VIth Oujda, University Mohammed Premier Oujda, Oujda-60000, Morocco.
Rachid Sekhsoukh
Department of Ophthalmology, Faculty of Medicine and Pharmacy, University Hospital Center Mohammed VIth Oujda, University Mohammed Premier Oujda, Oujda-60000, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Best macular dystrophy, also called vitelliform macular dystrophy, is an autosomal dominant disease described by Frederick Best in 1905. It classically occurs in childhood and is characterized by macular deposits of vitelline material. We report the case of a 5-year-old female patient with no particular pathologic history. Ophthalmologic examination revealed corrected visual acuity of 10/10 for both eyes, and anterior segment examination was unremarkable. Fundus examination revealed a yellowish oval macular lesion with an irregular grayish center on the right and a yellowish macular focus on the left. Autofluorescence images showed bilateral perifoveal hyperautofluorescence with central hypo fluorescence. Macular optical coherence tomography (OCT) showed serous retinal detachment with retinal pigment epithelium (RPE) changes in both eyes and a hyperreflective subretinal deposit in the left eye. Paraclinical examinations, including electrophysiologic testing and angiography, could not be performed because of the young age. On examination of the ocular fundus of the mother and uncle, we discovered different stages of the same pathology. Considering this discovery, the age, and the bilateral nature of the disease, the diagnosis of Best disease was suspected and confirmed by genetic testing, which revealed a BEST1 mutation. We suggested a simple surveillance of the patient and her mother and uncle.
Keywords: Best disease, EOG, vitelliform macular dystrophy, autosomal, dominant, lipofuscin, serous detachment, atrophy, fibrosis
How to Cite
References
Best FZ. Über eine hereditare Maculaaffektion: bietrage zur vererbungslehre. Z Augenheilkd 1905;13: 199-21.
François J, De Rouck A, Fernandez-Sasso D. Electro-oculography in vitelliform degeneration of the macula. Arch Ophthalmol. 1967;77:726-733.
Stöhr H, Marquardt A, Rivera A, Cooper PR, Nowak NJ, et al. A gene map of the Best's vitelliform macular dystrophy region in chromosome 11q12-q13.1. Genome Res. 1998;8:48-56.
Johnson AA, Guziewicz KE, Lee CJ, Kalathur RC, Pulido JS, Marmorstein LY, Marmorstein AD. Bestrophin 1 and retinal disease. Progress in Retinal and Eye Research. 2017;58:45–69.
Brunk UT, Wihlmark U, Wrigstad A, Roberg K, Nilsson SE. Accumulation of lipofuscin within retinal pigment epithelial cells results in enhanced sensitivity to photo-oxidation. Gerontology. 1995;41(2): 201–212.
Mohler CW, Fine SL. Long-term evaluation of patients with Best’s vitelliform dystrophy. Ophthalmology. 1981;88:688–92.
Deutman AF. Electro-oculography in families with vitelliform dystrophy of the fovea. Detection of the carrier state. Arch Ophthalmol. 1969;81:305– 16.
Besch D, Zrenner E. Best's disease. Orphanet Encyclopedia. 2005;1-5.
Leu J, Schrage NF. Degenring RF. Choroidal neovascularization secondary to Best's disease in a 13-year-old boy treated with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2007;245: 1723-5.
Andrade RE, Farah ME, Costa RA. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease. Am J Ophthalmol. 2003;136: 1179-1181.